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Abstract
Background: Increasing evidence suggests seizures cause blood–brain barrier (BBB) dysfunction including
decreased seizure threshold and higher onset potential of future seizures. However, the mechanisms underlying
BBB damage in seizures remains poorly understood. Evidence in human and animal models shows BBB disruption is
associated with activation of matrix metalloproteinase-9 (MMP-9) after cerebral ischemia and inflammation. The
objective of this study was to determine whether MMP-9 concentrations in cerebral spinal fluid (CSF) are associated
with BBB disruption in patients after epileptic seizures.
Methods: Thirty-one patients with generalized tonic-clonic (GTC) seizures were included in the study: 20 had
recurrent GTC seizures (RS), and 11 had a single GTC seizure (SS) episode. Twenty-five adult non-seizure patients
were used as controls. CSF samples were collected by lumbar puncture within 24 h after seizure cessation (range:
3–15 h, mean 6.2 h). CSF MMP-9 levels were determined by an enzyme-linked immunosorbent assay (ELISA). MMP
enzyme activity was measured by gelatin zymography. The CSF/serum albumin ratio (albumin quotient, QAlb) was
used as a measure of blood–brain barrier permeability.
Results: We found significantly higher CSF MMP-9 concentrations in seizure patients compared with controls
(P < 0.001). CSF MMP-9 levels and QAlb values were higher in RS patients compared with SS and controls.
Moreover, CSF MMP-9 concentration showed strong correlation between QAlb values (r = 0.76, P < 0.0001) and
between CSF leukocyte counts (r = 0.77, P < 0.0001) in patients after seizures. Gelatin zymography showed MMP-9
proteolytic activity only in GTC seizure patients.
Conclusions: Our results suggest MMP-9 plays a role in BBB dysfunction, characterized by invasion of leukocytes
into the CSF during seizures.
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Background
The blood–brain barrier (BBB) is the most important
vascular barrier of the central nervous system (CNS).
Due to its unique structure, the BBB limits penetration
of a variety of harmful substances from the blood into
the brain, while also supplying the brain with nutrients
required for proper function. In recent years, animal
models and human clinical data have described a central
role for vascular integrity, specifically the permeability of
the BBB, as an important mediator of brain damage, in-
cluding the delayed appearance of neuronal dysfunction
and death [1-4]. Studies show BBB dysfunction is com-
mon following traumatic, ischemic or infectious brain
insults, and it may last from several days to weeks and
even years after the acute event [5,6]. Recently, clinical
and experimental data have correlated primary BBB le-
sions with seizures and epileptogenesis. Experimental
studies have demonstrated a rapid increase in BBB per-
meability in animals experiencing long-lasting seizures,
especially status epilepticus (SE). Studies in human
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epileptic patients are consistent with the animal data,
showing an increase in BBB permeability during seizures
[7,8]. Pentylenetetrazole-induced seizures cause BBB dis-
ruption, allowing permeation of blood-borne large mole-
cules, such as albumin, into the CNS [9,10]. BBB
disruption decreases the seizure threshold and facilitates
the onset of seizures, and it is independent of the fact
that such disruption is associated with or a result of the
seizure itself [11]. The mechanisms underlying the BBB
disruption in seizures and epileptogenesis are not en-
tirely clear. There is evidence in human and animal
stroke models that BBB disruption is associated with
activation of matrix metalloproteinases (MMPs) [12-14].
MMPs are a family of zinc-dependent endopeptidases
that are subdivided according to their substrate affinities
for different components of the extracellular matrix.
Among the various MMPs, metalloproteinase-9 (MMP-9),
also known as gelatinase B, is thought to play an import-
ant role in BBB disruption after cerebral ischemia and in-
flammation [12,15-17]. MMP-9 degrades collagen IV, a
major component of the basement membrane of the cere-
bral epithelium that is responsible for the integrity of BBB.
The activity of MMP-9 is further controlled by the specific
tissue inhibitor TIMP-1. However, the link between CSF
MMP-9 levels and the presence of BBB disruption in
patients after seizures has not yet been investigated in
humans. Our study aimed to determine whether MMP-9
can be measured in CSF of patients after epileptic seizures
and whether there is a correlation between CSF MMP-9
levels and QAlb values in patients after epileptic seizures.
Methods
Patient recruitment
The study was performed at the Department of Neurology
of the Affiliated Hospital of Xi’an Medical University.
Thirty-one patients with either tonic-clonic or partial sec-
ondarily generalized seizures were included in the study:
20 had recurrent GTC seizures (RS), and 11 had a single
GTC seizure (SS) episode confirmed by an eyewitness that
occurred within 3 h before admission. On admission to
the emergency ward, all seizure patients received standard
intravenous treatment with diazepam (dose range 10–20
mg) to stop seizure activity. Then patients were admitted
to a neurologic ward for further evaluation. All patients
underwent a standard diagnostic workup including neuro-
logic examination and blood biochemical assessment. Ten
patients presented the first-ever epileptic seizure and
underwent further examinations including electroenceph-
alography (EEG) and either a computed tomography (CT)
or magnetic resonance imaging (MRI) scan, and the final
diagnosis of epilepsy was confirmed (8 with cryptogenic
localization-related epilepsy and 2 with idiopathic general-
ized epilepsy). Twenty-one patients already had an epi-
lepsy diagnosis: 6 with cryptogenic localization-related
epilepsy and 15 with symptomatic localization-related epi-
lepsy with secondary generalization. Those patients pre-
senting apparent symptomatic etiology of seizures, that is,
electrolyte disturbances, defined metabolic causes, drug
intoxication, infections, trauma or abnormal CT or MRI
suggestive of acute brain diseases were excluded. All pa-
tients were studied within 24 h after the seizure. Epilepsy
was diagnosed and classified according to the criteria pro-
posed by the International League Against Epilepsy in
2011 [18]. Seizures and epileptic syndromes were classified
according to the ILAE diagnostic criteria.
The control samples were obtained from 25 adult
patients (mean age 39 ±13.6 years; range 16–56 years)
by lumbar puncture and examined to exclude those with
neurological disease, including nonspecific symptoms
without diagnosed organic neurologic disease (n = 7), per-
ipheral nervous system disorders (n = 4), acute headache
(n = 5), spontaneous intracranial hypotension (n = 3),
compressive radiculopathy (n = 4) and primary dementia
(n = 2). All controls had normal neurological examination
and normal CSF results on routine analysis.
All epileptic patients and controls were fully informed
of the risks and potential benefits of the CSF examination
as part of the diagnostic workup. Informed consent to
participate in the study was obtained from each subject
(or from the next of kin if the patient was incapable). Five
patients were considered for the study but did not agree
to undergo lumbar puncture and were not included in the
study. The study protocol was approved by the Ethics
Committee of the Affiliated Hospital of Xi’an Medical
University, and all investigations were done in accordance
with the criteria of the Declaration of Helsinki.
CSF/serum sampling and biochemical analysis
CSF samples were taken between 10 a.m. and 5 p.m. by
lumbar puncture from the L3/L4 or L4/L5 inter-
vertebral space. Lumbar puncture was performed within
24 h after seizure cessation (range: 3–15 h, mean 6.2 h).
CSF samples that were not clear or initially contained
blood with gradual clearing were excluded from analysis.
The first 2 ml of CSF was used for routine clinical tests
and the subsequent 0.5 ml for our study. The CSF white
blood cell (WBC) count, differential leukocyte count,
total protein concentration, glucose (Glu) and chloride
(CL) values were determined by standard methods im-
mediately after lumbar puncture. Cytology of CSF cells
was also performed. CSF and peripheral blood samples
were collected simultaneously and centrifuged for 10
min at 2,500 g; 500 μl of the cell-free samples was im-
mediately frozen and stored at −80°C until analysis.
Concentrations of MMP-9 were measured by commer-
cial enzyme-linked immunosorbent assay (ELISA) kits
(R & D Systems, Minneapolis, MN) performed according
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to the manufacturer’s instructions. Optical density
values were determined with a microplate reader set to
450 nm.
Measurement of the QAlb value
Quantitative determination of albumin in the CSF and
serum of all specimens were measured by a commer-
cial kit (BioAssay Systems, Hayward, CA). The CSF/
serum albumin ratio (albumin quotient, QAlb) was
used as a measure of blood–brain barrier permeability.
QAlb was calculated using the formula: QAlb = CSFAlb/
serum Alb × 103.
Gelatin zymography
Activity of MMP-2 and MMP-9 enzymes in CSF samples
was determined by gelatin zymography as previously de-
scribed [16]. Briefly, activity of MMPs was analyzed by
modified sodium dodecyl sulfate-polyacrylamide gel
electrophoresis. Stacking gels contained 4% polyacryl-
amide, and separating gels contained 12.5% polyacryl-
amide and 0.1% gelatin. The 2 ml CSF was centrifuged
at 10,000 × g for 15 min at 4°C to remove debris. Protein
contents of supernatants were then mixed with an equal
volume of 2× non-reducing sample buffer, and 25 μl was
loaded per well. The gels underwent electrophoresis at
90 V and 4°C in running buffer (25 mM Tris, 250 mM gly-
cine, 0.1% sodium dodecyl sulfate) until the bromophenol
blue marker dye reached the bottom of the gel. After
electrophoresis, the gel was transferred into a 2.5% Triton
X-100 wash for 1 h at room temperature. After decanting
the washing solution, the gel was equilibrated with devel-
oping buffer (50 mM Tris–HCl, pH 7.5, 200 mM NaCl, 5
mM CaCl2, 0.02% Brij-35, 0.01% NaN3) for 30 min at
room temperature with gentle agitation. The gel was then
placed in fresh developing buffer and incubated at 37°C
for 18 h. The gel was stained for 1 h with 0.25%
Coomassie Brilliant Blue R-250 (Sigma, St. Louis, MO)
and was destained in 15% methanol/7.5% acetic acid.
MMP activity was detected as white bands of lysis against
the Coomassie blue-stained gel. The CSF zymography ex-
periments were performed in triplicate. The gels were dig-
italized and the integrated density of the bands expressed
as arbitrary units. The intensities of the gelatinolytic bands
corresponding to MMP-9 and MMP-2 were calculated
using the open-access software Image J 1.46r (National
Institutes of Health, Bethesda, MD, USA; http://rsb.info.
nih.gov/ij).
Statistical analysis
Data are presented as mean ± SD for normally distributed
and non-parametric data. Student's t-test and Mann–
Whitney U-test were used for comparison of normally dis-
tributed and non-parametric data, respectively, between
groups. ANOVA and Kruskal-Wallis test were used for
comparison of normally distributed and non-parametric
data, respectively, between multiple groups. Spearman's
correlation coefficient was used to correlate variables in
the groups studied. The calculations were performed with
GraphPadInStat version 3.05 software (GraphPad Soft-
ware, Inc., San Diego, CA, USA). For all tests, P < 0.05
was considered significant.
Results
Demographics of study participants
Demographic details of patients with epilepsy and con-
trols are presented in Table 1. Thirty-one seizure pa-
tients and 25 controls provided data for the study. The
mean age of the seizure patients was 42.5 (range, 20–68)
years, and 16 (44%) were women. Among the controls,
mean age was 38.7 (range, 22–71) years, and 12 (48%)
were women. There were no differences between the two
groups for these demographics. Twelve patients were
receiving monotherapy, 9 polytherapy (the mean number
of medications 2.3) and 10 patients no medication.
MMP-9 concentrations and QAlb values are higher in
seizure patients
We measured significantly higher MMP-9 concentrations
(Table 2 and Figure 1A; P < 0.001) and QAlb values
(Table 2 and Figure 2A) in seizure patients compared with
Table 1 Clinical characteristics of seizure patients and
control subjects
Variable Patient Control P value
Number (n) 31 25
Current age (years) 42.5 (15.1) 38.7 (17.6) P > 0.05
Age at onset of epilepsy (years) 23.3 (14.8)
Gender (M:F), n 20/16 13/12 P > 0.05
Red blood cells (1012/l) 4.3 4.5 P > 0.05
White blood cells (109/l) 5.9 6.2 P > 0.05
Focus of seizure
Temporal, n (%) 13 (41.9)
Extratemporal, n (%) 18 (58.1)
Type of seizure
Single GTC seizure, n (%) 11 (35.5)
Repetitive GTC seizure, n (%) 20 (64.5)
Epilepsy duration (years) 6.3 (1–18)
Frequency of seizures (month) 1.5 (1–5)
Number of seizures 3.3 (1–10)
Total duration of seizure (min) 8.3 (2–13)
Time to sampling (h) 6.2 (3–15)
Anti-epileptic drugs used 21 (67.7)
No treatment 10 (32.3)
Mann–Whitney U-test for continuous variables; cross tabulations and chi-
square-test for categorical variables.
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controls. We found significantly higher concentrations of
MMP-9 (Figure 1B) and QAlb values (Figure 2B) in RS pa-
tients compared with SS and controls (Figure 1B). Analysis
of temporal epilepsy and extra-temporal epilepsy showed
no significant difference in CSF MMP-9 (Figure 1C) or
QAlb values (Figure 2C). In addition, when considering
use of anti-epileptic drugs (AEDs), we found no difference
in MMP-9 levels (Figure 1D) or QAlb values (Figure 2D).
All seizure patients had normal serum protein and albu-
min concentrations. These data suggest that the CSF albu-
min increase was regulated by the increased permeability
of the damaged BBB.
MMP-9 concentrations and QAlb values are correlated
To determine if the increased MMP-9 levels and higher
QAlb values were related, we performed correlation
Table 2 The mean concentrations of CSF MMP-9, CSF cell count and albumin, and serum albumin from patients with
GTC seizures and controls
Variable Patient (mean ± SD) Control (mean ± SD) P
CSF leukocytes (106/l) 8.2 ± 2.3 2.0036 ± 1.4 <0.05
CSF erythrocytes (106/l) 19.6 ± 30.5 14.4 ± 21.8 >0.05
CSF albumin (g/l) 278.6 ± 35.5 (×10-3) 198.2 ± 48.7 (×10-3) <0.05
Serum albumin (g/l) 41.6 ± 1.3 42.3 ± 1.5 >0.05
QAlb 8.35 ± 2.6 (×10-3) 4.7 ± 1.4 (×10-3) <0.001
MMP-9 (ng ⁄ml) 7.0 ± 2.4 1.80 ± 0.63 <0.001
Patient compared to control by Mann–Whitney test.
Figure 1 CSF MMP-9 levels in seizure patients and controls. (A) Boxplot representing the distribution (median and interquartile range) of CSF
MMP-9 concentrations for control subjects (Control) and seizure patients (Epilepsy). Significantly higher MMP-9 levels in seizure patients
compared with controls are shown. (B) Patients with repetitive generalized tonic-clonic seizures tended to have higher CSF MMP-9 levels
compared with those who had single generalized tonic-clonic seizure and controls. (C) No significant difference found between temporal and
extratemporal epilepsy (P > 0.05). (D) No significant difference between AEDs treatment groups (P > 0.05). Horizontal line indicates median.
Significant change at P < 0.001 using Mann–Whitney U tests.
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analysis. We found a strong correlation between MMP-9
concentration and QAlb values in patients after GTC
seizures (Figure 3A, r = 0.76, P < 0.001). We also found a
correlation between CSF MMP-9 concentration and
leukocyte counts in patients after GTC seizures (Figure 3B,
r = 0.77, P < 0.001). In fact, our data show the greater
number of leukocytes in the CSF aligned with higher
MMP-9 concentrations. These results suggest leukocytes
are the source of increased MMP-9 levels in CSF after
seizure.
We also looked at the correlation between CSF MMP-9
levels and seizure frequency and correlation between
QAlb values and seizure frequency. We found that neither
CSF MMP-9 levels nor QAlb values correlated with seiz-
ure frequency (Figure 3C-D).
MMP-9 enzyme activity detected in seizure samples
We randomly selected CSF specimens from two patients
and two controls for enzyme activity analysis by gelatin
zymography. As shown in Figure 4, all CSF specimens
from patients and controls show a band at molecular
mass 72 kD, representing MMP-2. However, only CSF
specimens from patients after seizure showed MMP-9
activity. We found that RS and SS samples had a higher
ratio of active/inactive MMP-9 activity, supporting the
argument that higher MMP-9 levels and the severity of
BBB damage are dependent on the number of seizure in-
sults but not MMP-2. Interestingly, polymorphonuclear
neutrophils were present in 42% of patient CSF samples.
This confirms a transient influx of neutrophils into the
CSF of patients after epileptic seizure.
Discussion
Many questions are unanswered regarding how BBB in-
tegrity changes during epileptic seizures. And it is unclear
whether elevated CSF MMP-9 contributes to alterations
in BBB permeability. Our study addresses these questions
by demonstrating, in vivo, a marked dysfunction of the
BBB with significantly higher MMP-9 in CSF after epilep-
tic seizures. To our knowledge, this is the first prospective
study of the link between CSF MMP-9 and BBB dysfunc-
tion in patients after epileptic seizure.
Figure 2 Mean QAlb values in seizure patients and controls. (A) Boxplot representing the distribution (median and interquartile range) of
QAlb for control and epilepsy patients. QAlb values were higher in the epilepsy group than in controls. (B) Patients with repetitive GTC seizures
had higher QAlb values than those with a single GTC seizure. (C) No significant difference found between temporal and extratemporal epilepsy
(P > 0.05). (D) No difference measured between AEDs treatment groups (P > 0.05). Horizontal line indicates median; significant P-values among
groups are displayed (Mann–Whitney test).
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Figure 3 Correlation analysis of CSF MMP-9 levels in seizure patients. (A) Significant correlation between CSF MMP-9 levels and QAlb value
(P < 0.0001, r = 0.77). (B) Significant correlation between CSF MMP-9 levels and CSF leukocyte count (P < 0.0001, r =0.76). (C) No significant
correlation between CSF MMP-9 levels and seizure frequency (P = 0.846, r = 0.036). (D) No significant correlation between QAlb value and seizure
frequency ( P = 0.424, r = 0.149). Correlation analysis performed with Spearman’s rank correlation coefficient.
Figure 4 MMP enzyme activity of CSF samples. Top panel: Gelatin zymography gel results. Lane 1: GTC seizure sample; lanes 2 and 3 are
controls; lane 4: single GTC seizure sample. Note that only seizure samples had positive MMP activity. (A) The relative optical density of MMP-9.
(B) The relative optical density of MMP-2.
Li et al. Journal of Neuroinflammation 2013, 10:80 Page 6 of 9
http://www.jneuroinflammation.com/content/10/1/80
A dysfunctional BBB leads to increased permeability,
allowing increased CSF marker passage. Therefore, CSF
protein levels are a reliable way to monitor BBB integrity
without using invasive methods. A common and well-
established assessment of BBB function measures the
level of albumin, a blood-specific protein in CSF and
serum, reported as the CSF/serum albumin ratio (QAlb)
[19,20]. An increase in QAlb reflects the serum albumin
leakage in CSF due to BBB dysfunction, especially
blood-CSF barrier dysfunction [21-23]. Previous studies
have shown increased QAlb is correlated with status
epilepticus [7]. In our study, we found the QAlb value
was significantly increased in patients after seizure,
suggesting BBB dysfunction after epileptic seizure. This
finding is consistent with histological studies showing
albumin accumulation in human epileptic brains [24,25].
Ultrastructural studies on human resected epileptic tissue
also show clear BBB abnormalities, including increased
micropinocytosis and the presence of abnormal tight junc-
tions [26,27].
Accumulating experimental evidence indicates BBB
dysfunction and inflammatory mediators decrease the
threshold for individual seizures and contribute to
epileptogenesis. Thus, BBB breakdown is regarded as
an important pathophysiological event in seizures and
epileptogenesis. Therefore, understanding the mechanisms
controlling BBB disruption is critical to the understanding
of epileptogenesis and may lead to new therapeutic targets
for the prevention and treatment of epilepsy.
Matrix metallopeptidases (MMPs) represent a family of
extracellular soluble or membrane bound neutral prote-
ases having complex functions in normal and pathological
conditions. Among MMPs, MMP-2 and MMP-9 are the
only two gelatinases in humans. MMP-2 is normally found
in brain and CSF [28]. In our study we found MMP-2 in
the control CSF and in the patient CSF, indicating that
expression of CSF MMP-2 in patients was not a result of
seizure. MMP-9 is most abundantly expressed in the de-
veloping brain and is produced mainly by neurons and, to
some extent, by glial cells in the CNS [29-31]. Under
normal physiological conditions, MMP-9 is involved in
dendritic spine remodeling, synaptic plasticity, learning
and memory formation [32-35]. Increasing evidence in ex-
perimental animal models of epilepsy and human epileptic
brains shows that MMP-9 plays a role in the pathogenesis
of epilepsy by contributing to neuronal death, aberrant
synaptic plasticity and neuroinflammation [36-39]. One
study found that MMP-9 participates in the occurrence
of seizures by converting pro-BDNF to mature BDNF in
the hippocampus [38]. BDNF contributes to epilepsy in
many ways. The roles of BDNF are not only important
in acute seizures and epileptogenesis, but are also likely
to be important in chronic epilepsy. Increased levels of
BDNF exert functional effects that are consistent with a
pro-convulsant action. Animal model studies suggest
intrahippocampal infusion of BDNF, and transgenic
overexpression of BDNF significantly increases seizure
susceptibility and severity [40-43]. Other studies have
reported MMP-9-induced cell death is closely linked
with the pathogenesis of epilepsy after SE [34,44]. In
particular, MMP-9 knockout mice were less susceptible
to seizure-induced brain injury, and MMP-9 inhibition
ameliorated cell death following pilocarpine-induced
seizures in infant rats [34]. Further, MMP-9 plays an
important role in epileptogeness mainly due to MMP-9-
related synaptic plasticity changes rather than neuronal
death [45]. However, the relationship between CSF
MMP-9 and BBB dysfunction in patients after epileptic
seizures remains unclear.
A growing body of experimental and clinical evidence
shows MMP-9 plays a major role in BBB disruption in a
variety of pathological conditions including CNS infec-
tions [46-48], stroke [12,15,49,50], multiple sclerosis [51]
and traumatic brain injury [52]. MMP-9 cleaves type IV
collagen, a major component of the basement membrane
of the cerebral epithelium that is responsible for the
integrity of the BBB. MMP-9 also degrades a number of
other extracellular matrix molecules including type V
and XI collagens, laminin and aggrecan core protein
[29,53,54]. Our study confirms a strong correlation be-
tween CSF MMP-9 levels and BBB dysfunction in patients
after GTC seizures and argues MMP-9, not MMP-2, plays
a role in BBB disruption during seizures.
Here, we also confirmed a transient influx of granulocytes
into CSF of patients after epileptic seizure. Neutrophils in
CSF samples are commonly considered a pathological fea-
ture. The migration of leukocytes from the bloodstream
into the CNS is a key event in the pathogenesis of inflam-
matory neurological diseases. Recent data suggest that
leukocyte-endothelial interaction and brain infiltration by
leukocytes plays an important role in the pathogenesis of
epilepsy [55-57]. In our study, we also found that elevated
MMP-9 levels in CSF are primarily related to the number
of immigrated leukocytes, with positive correlation be-
tween CSF MMP-9 levels and CSF leukocytes as well as
between CSF MMP-9 levels and QAlb values. Leukocytes
contribute to seizure pathogenesis acutely through affects
on the BBB and chronically through several mechanisms
including generation of oxygen free radicals, release of
cytotoxic enzymes, vascular alterations and increase in
cytokine and chemoattractant release [58]. Thus, we con-
firm that increased CSF MMP-9 represents the accumula-
tion of activated leukocytes. It is reasonable to suspect
that leukocytes are major producers of MMP-9. Further-
more, it has been demonstrated that injured neuronal and
glial cells are major sources of MMP-9, supporting the
neuroinflammatory response by releasing cytokines during
epileptic seizures [36,37,53]. Indeed, we observed MMP-9
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activity in CSF specimens from patients with seizures
only.
We also analyzed effects of antiepileptic drugs (AEDs)
on CSF MMP-9 concentrations and found no significant
MMP-9 changes in patients with seizure. It is important
to note several other reports show AEDs inhibit MMP-9
production and protect BBB function in epileptic patients
and cerebral ischemic rats [59,60]. It has been proposed
that MMP-9 is involved in aberrant synaptic formation in
hippocampi of patients with temporal lobe epilepsy [39].
Therefore, we also analyzed temporal and extra-temporal
seizures. Our findings show no differences in CSF MMP-9
levels between patients with temporal seizures and pa-
tients with extra-temporal seizures. In general, our find-
ings argue MMP-9 overexpression is associated with
activation of leukocytes, most likely polymorphonuclear,
that serve as a key cellular source of MMP-9 in CSF. In
turn, this promotes leukocyte recruitment, causing BBB
breakdown, microvascular basal lamina proteolysis, and
ultimately contributes to neuronal injury after epileptic
seizure.
Conclusions
In this study, we found a significant correlation between
CSF MMP-9 concentrations and CSF leukocyte counts,
leading to BBB dysfunction. We suggest increased con-
centrations of MMP-9 in CSF were partly derived from
leukocytes. These results demonstrate that seizure is
characterized by invasion of leukocytes into the CSF and
increased CSF MMP-9 levels are associated with BBB
dysfunction in patients with seizures.
Competing interests
The authors declared that they have no competing interest.
Authors’ contributions
YJL designed the research, ZHW reviewed and helped in analyzing data, BZ,
XZ, MJW and STS processed serum and CSF from the patients and controls,
JB, TL, CJG, SJZ, XLK, XZ and HZ performed the research, and YJL and ZHW
wrote the paper. All authors read and approved the final manuscript.
Acknowledgments
This work was supported by grants from Natural Science Foundation of
Shaanxi Province (no. 2009JM4035) and Science and Technology Plan
Projects of the Shaanxi Provincial Department of Education (no. 07JK372),
and from Science and Technology Project of Xi'an Lianhu District
(no. K2011–024). We thank Dr. Austin Cape for careful reading and insightful
feedback.
Author details
1Department of Neurology, The Affiliated Hospital of Xi’an Medical University,
No. 48, West Fenghao Road, Xi’an 710077, Shaanxi Province, China.
2Department of Neurology, The General Hospital of Ningxia Medical
University, Ningxia, China.
Received: 5 October 2012 Accepted: 24 June 2013
Published: 5 July 2013
References
1. Abbott NJ, Ronnback L, Hansson E: Astrocyte-endothelial interactions at
the blood–brain barrier. Nat Rev Neurosci 2006, 7:41–53.
2. Hawkins BT, Davis TP: The blood–brain barrier/neurovascular unit in
health and disease. Pharmacol Rev 2005, 57:173–185.
3. Tomkins O, Shelef I, Kaizerman I, Eliushin A, Afawi Z, Misk A, Gidon M,
Cohen A, Zumsteg D, Friedman A: Blood–brain barrier disruption in post-
traumatic epilepsy. J Neurol Neurosurg Psychiatry 2008, 79:774–777.
4. van Vliet EA, da Costa AS, Redeker S, van Schaik R, Aronica E, Gorter JA:
Blood–brain barrier leakage may lead to progression of temporal lobe
epilepsy. Brain 2007, 130:521–534.
5. Korn A, Golan H, Melamed I, Pascual-Marqui R, Friedman A: Focal cortical
dysfunction and blood–brain barrier disruption in patients with
postconcussion syndrome. J Clin Neurophysiol 2005, 22:1–9.
6. Strbian D, Durukan A, Pitkonen M, Marinkovic I, Tatlisumak E, Pedrono E,
Abo-Ramadan U, Tatlisumak T: The blood–brain barrier is continuously
open for several weeks following transient focal cerebral ischemia.
Neuroscience 2008, 153:175–181.
7. Correale J, Rabinowicz AL, Heck CN, Smith TD, Loskota WJ, DeGiorgio CM:
Status epilepticus increases CSF levels of neuron-specific enolase and
alters the blood–brain barrier. Neurology 1998, 50:1388–1391.
8. Friedman A: Blood–brain barrier dysfunction, status epilepticus, seizures, and
epilepsy: a puzzle of a chicken and egg? Epilepsia 2011, 52(Suppl 8):19–20.
9. Sahin D, Ilbay G, Ates N: Changes in the blood–brain barrier permeability
and in the brain tissue trace element concentrations after single and
repeated pentylenetetrazole-induced seizures in rats. Pharmacol Res 2003,
48:69–73.
10. Marchi N, Angelov L, Masaryk T, Fazio V, Granata T, Hernandez N, Hallene K,
Diglaw T, Franic L, Najm I, Janigro D: Seizure-promoting effect of blood–
brain barrier disruption. Epilepsia 2007, 48:732–742.
11. Marchi N, Tierney W, Alexopoulos AV, Puvenna V, Granata T, Janigro D: The
etiological role of blood–brain barrier dysfunction in seizure disorders.
Cardiovasc Psychiatry Neurol 2011, 2011:482415.
12. Barr TL, Latour LL, Lee KY, Schaewe TJ, Luby M, Chang GS, El-Zammar Z,
Alam S, Hallenbeck JM, Kidwell CS, Warach S: Blood–brain barrier
disruption in humans is independently associated with increased matrix
metalloproteinase-9. Stroke 2010, 41:e123–e128.
13. Aoki T, Sumii T, Mori T, Wang X, Lo EH: Blood–brain barrier disruption and
matrix metalloproteinase-9 expression during reperfusion injury:
mechanical versus embolic focal ischemia in spontaneously
hypertensive rats. Stroke 2002, 33:2711–2717.
14. Jin R, Yang G, Li G: Molecular insights and therapeutic targets for blood–
brain barrier disruption in ischemic stroke: critical role of matrix
metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis
2010, 38:376–385.
15. Gidday JM, Gasche YG, Copin JC, Shah AR, Perez RS, Shapiro SD, Chan PH,
Park TS: Leukocyte-derived matrix metalloproteinase-9 mediates blood–
brain barrier breakdown and is proinflammatory after transient focal
cerebral ischemia. Am J Physiol Heart Circ Physiol 2005, 289:H558–H568.
16. Tsai HC, Chung LY, Chen ER, Liu YC, Lee SS, Chen YS, Sy CL, Wann SR, Yen
CM: Association of matrix metalloproteinase-9 and tissue inhibitors of
metalloproteinase-4 in cerebrospinal fluid with blood–brain barrier
dysfunction in patients with eosinophilic meningitis caused by
Angiostrongylus cantonensis. Am J Trop Med Hyg 2008, 78:20–27.
17. Fernandez-Lopez D, Faustino J, Daneman R, Zhou L, Lee SY, Derugin N,
Wendland MF, Vexler ZS: Blood–brain barrier permeability is increased
after acute adult stroke but not neonatal stroke in the rat. J Neurosci
2012, 32:9588–9600.
18. Berg AT, Scheffer IE: New concepts in classification of the epilepsies:
entering the 21st century. Epilepsia 2011, 52:1058–1062.
19. Tibbling G, Link H, Ohman S: Principles of albumin and IgG analyses in
neurological disorders. I. Establishment of reference values. Scand J Clin
Lab Invest 1977, 37:385–390.
20. Ganrot K, Laurell CB: Measurement of IgG and albumin content of
cerebrospinal fluid, and its interpretation. Clin Chem 1974, 20:571–573.
21. Chalbot S, Zetterberg H, Blennow K, Fladby T, Andreasen N, Grundke-Iqbal I,
Iqbal K: Blood-cerebrospinal fluid barrier permeability in Alzheimer's
disease. J Alzheimers Dis 2011, 25:505–515.
22. Sindic CJ, Van Antwerpen MP, Goffette S: The intrathecal humoral immune
response: laboratory analysis and clinical relevance. Clin Chem Lab Med
2001, 39:333–340.
23. Reiber H, Padilla-Docal B, Jensenius JC, Dorta-Contreras AJ: Mannan-
binding lectin in cerebrospinal fluid: a leptomeningeal protein.
Fluids Barriers CNS 2012, 9:17.
Li et al. Journal of Neuroinflammation 2013, 10:80 Page 8 of 9
http://www.jneuroinflammation.com/content/10/1/80
24. Raabe A, Schmitz AK, Pernhorst K, Grote A, von der Brelie C, Urbach H,
Friedman A, Becker AJ, Elger CE, Niehusmann P: Cliniconeuropathologic
correlations show astroglial albumin storage as a common factor in
epileptogenic vascular lesions. Epilepsia 2012, 53:539–548.
25. Marchi N, Teng Q, Ghosh C, Fan Q, Nguyen MT, Desai NK, Bawa H,
Rasmussen P, Masaryk TK, Janigro D: Blood–brain barrier damage, but not
parenchymal white blood cells, is a hallmark of seizure activity. Brain Res
2010, 1353:176–186.
26. Cornford EM: Epilepsy and the blood–brain barrier: endothelial cell
responses to seizures. Adv Neurol 1999, 79:845–862.
27. Heinemann U, Kaufer D, Friedman A: Blood–brain barrier dysfunction,
TGFbeta signaling, and astrocyte dysfunction in epilepsy. Glia 2012,
60:1251–1257.
28. Grossetete M, Phelps J, Arko L, Yonas H, Rosenberg GA: Elevation of matrix
metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients
with severe traumatic brain injury. Neurosurgery 2009, 65:702–708.
29. Dong X, Song YN, Liu WG, Guo XL: Mmp-9, a potential target for cerebral
ischemic treatment. Curr Neuropharmacol 2009, 7:269–275.
30. Michaluk P, Kaczmarek L: Matrix metalloproteinase-9 in glutamate-
dependent adult brain function and dysfunction. Cell Death Differ 2007,
14:1255–1258.
31. Szklarczyk A, Lapinska J, Rylski M, McKay RD, Kaczmarek L: Matrix
metalloproteinase-9 undergoes expression and activation during
dendritic remodeling in adult hippocampus. J Neurosci 2002, 22:920–930.
32. Michaluk P, Wawrzyniak M, Alot P, Szczot M, Wyrembek P, Mercik K,
Medvedev N, Wilczek E, De Roo M, Zuschratter W, et al: Influence of matrix
metalloproteinase MMP-9 on dendritic spine morphology. J Cell Sci 2011,
124:3369–3380.
33. Wang XB, Bozdagi O, Nikitczuk JS, Zhai ZW, Zhou Q, Huntley GW:
Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic
spine enlargement and long-term potentiation coordinately. Proc Natl
Acad Sci U S A 2008, 105:19520–19525.
34. Hoehna Y, Uckermann O, Luksch H, Stefovska V, Marzahn J, Theil M,
Gorkiewicz T, Gawlak M, Wilczynski GM, Kaczmarek L, Ikonomidou C: Matrix
metalloproteinase 9 regulates cell death following pilocarpine-induced
seizures in the developing brain. Neurobiol Dis 2012, 48:339–347.
35. Nagy V, Bozdagi O, Matynia A, Balcerzyk M, Okulski P, Dzwonek J, Costa RM,
Silva AJ, Kaczmarek L, Huntley GW: Matrix metalloproteinase-9 is required
for hippocampal late-phase long-term potentiation and memory.
J Neurosci 2006, 26:1923–1934.
36. Konopka A, Grajkowska W, Ziemianska K, Roszkowski M, Daszkiewicz P, Rysz
A, Marchel A, Koperski L, Wilczynski GM, Dzwonek J: Matrix
metalloproteinase-9 (MMP-9) in human intractable epilepsy caused by
focal cortical dysplasia. Epilepsy Res 2013, 104:45–58.
37. Li S, Yu S, Zhang C, Shu H, Liu S, An N, Yang M, Yin Q, Yang H: Increased
expression of matrix metalloproteinase 9 in cortical lesions from patients
with focal cortical dysplasia type IIb and tuberous sclerosis complex.
Brain Res 2012, 1453:46–55.
38. Mizoguchi H, Nakade J, Tachibana M, Ibi D, Someya E, Koike H, Kamei H,
Nabeshima T, Itohara S, Takuma K, et al: Matrix metalloproteinase-9
contributes to kindled seizure development in pentylenetetrazole-
treated mice by converting pro-BDNF to mature BDNF in the
hippocampus. J Neurosci 2011, 31:12963–12971.
39. Wilczynski GM, Konopacki FA, Wilczek E, Lasiecka Z, Gorlewicz A, Michaluk P,
Wawrzyniak M, Malinowska M, Okulski P, Kolodziej LR, et al: Important role
of matrix metalloproteinase 9 in epileptogenesis. J Cell Biol 2008,
180:1021–1035.
40. Lahteinen S, Pitkanen A, Koponen E, Saarelainen T, Castren E: Exacerbated
status epilepticus and acute cell loss, but no changes in epileptogenesis,
in mice with increased brain-derived neurotrophic factor signaling.
Neuroscience 2003, 122:1081–1092.
41. Scharfman HE, Goodman JH, Sollas AL, Croll SD: Spontaneous limbic
seizures after intrahippocampal infusion of brain-derived neurotrophic
factor. Exp Neurol 2002, 174:201–214.
42. Croll SD, Suri C, Compton DL, Simmons MV, Yancopoulos GD, Lindsay RM,
Wiegand SJ, Rudge JS, Scharfman HE: Brain-derived neurotrophic factor
transgenic mice exhibit passive avoidance deficits, increased seizure
severity and in vitro hyperexcitability in the hippocampus and
entorhinal cortex. Neuroscience 1999, 93:1491–1506.
43. Xu B, Michalski B, Racine RJ, Fahnestock M: The effects of brain-derived
neurotrophic factor (BDNF) administration on kindling induction, Trk
expression and seizure-related morphological changes. Neuroscience
2004, 126:521–531.
44. Kim GW, Kim HJ, Cho KJ, Kim HW, Cho YJ, Lee BI: The role of MMP-9 in
integrin-mediated hippocampal cell death after pilocarpine-induced
status epilepticus. Neurobiol Dis 2009, 36:169–180.
45. Takacs E, Nyilas R, Szepesi Z, Baracskay P, Karlsen B, Rosvold T, Bjorkum AA,
Czurko A, Kovacs Z, Kekesi AK, Juhasz G: Matrix metalloproteinase-9
activity increased by two different types of epileptic seizures that do not
induce neuronal death: a possible role in homeostatic synaptic plasticity.
Neurochem Int 2010, 56:799–809.
46. Paul R, Lorenzl S, Koedel U, Sporer B, Vogel U, Frosch M, Pfister HW: Matrix
metalloproteinases contribute to the blood–brain barrier disruption
during bacterial meningitis. Ann Neurol 1998, 44:592–600.
47. Matsuura E, Umehara F, Hashiguchi T, Fujimoto N, Okada Y, Osame M:
Marked increase of matrix metalloproteinase 9 in cerebrospinal fluid of
patients with fungal or tuberculous meningoencephalitis. J Neurol Sci
2000, 173:45–52.
48. Brown HC, Chau TT, Mai NT, Day NP, Sinh DX, White NJ, Hien TT, Farrar J,
Turner GD: Blood–brain barrier function in cerebral malaria and CNS
infections in Vietnam. Neurology 2000, 55:104–111.
49. Guo M, Cox B, Mahale S, Davis W, Carranza A, Hayes K, Sprague S, Jimenez
D, Ding Y: Pre-ischemic exercise reduces matrix metalloproteinase-9
expression and ameliorates blood–brain barrier dysfunction in stroke.
Neuroscience 2008, 151:340–351.
50. Wang Z, Meng CJ, Shen XM, Shu Z, Ma C, Zhu GQ, Liu HX, He WC, Sun XB,
Huo L, et al: Potential contribution of hypoxia-inducible factor-1alpha,
aquaporin-4, and matrix metalloproteinase-9 to blood–brain barrier
disruption and brain edema after experimental subarachnoid
hemorrhage. J Mol Neurosci 2012, 48:273–280.
51. Fainardi E, Castellazzi M, Bellini T, Manfrinato MC, Baldi E, Casetta I, Paolino
E, Granieri E, Dallocchio F: Cerebrospinal fluid and serum levels and
intrathecal production of active matrix metalloproteinase-9 (MMP-9) as
markers of disease activity in patients with multiple sclerosis. Mult Scler
2006, 12:294–301.
52. Higashida T, Kreipke CW, Rafols JA, Peng C, Schafer S, Schafer P, Ding JY,
Dornbos D 3rd, Li X, Guthikonda M, et al: The role of hypoxia-inducible
factor-1alpha, aquaporin-4, and matrix metalloproteinase-9 in blood–
brain barrier disruption and brain edema after traumatic brain injury.
J Neurosurg 2011, 114:92–101.
53. Yin P, Yang L, Zhou HY, Sun RP: Matrix metalloproteinase-9 may be a
potential therapeutic target in epilepsy. Med Hypotheses 2011, 76:184–186.
54. Ralay Ranaivo H, Hodge JN, Choi N, Wainwright MS: Albumin induces
upregulation of matrix metalloproteinase-9 in astrocytes via MAPK and
reactive oxygen species-dependent pathways. J Neuroinflammation 2012,
9:68.
55. Silverberg J, Ginsburg D, Orman R, Amassian V, Durkin HG, Stewart M:
Lymphocyte infiltration of neocortex and hippocampus after a single
brief seizure in mice. Brain Behav Immun 2010, 24:263–272.
56. Zattoni M, Mura ML, Deprez F, Schwendener RA, Engelhardt B, Frei K,
Fritschy JM: Brain infiltration of leukocytes contributes to the
pathophysiology of temporal lobe epilepsy. J Neurosci 2011,
31:4037–4050.
57. Fabene PF, Navarro Mora G, Martinello M, Rossi B, Merigo F, Ottoboni L,
Bach S, Angiari S, Benati D, Chakir A, et al: A role for leukocyte-endothelial
adhesion mechanisms in epilepsy. Nat Med 2008, 14:1377–1383.
58. Fabene PF, Laudanna C, Constantin G: Leukocyte trafficking mechanisms
in epilepsy. Mol Immunol 2013, 55:100–104.
59. Takahashi Y, Imai K, Ikeda H, Kubota Y, Yamazaki E, Susa F: Open study of
pranlukast add-on therapy in intractable partial epilepsy. Brain Dev 2013,
35:236–244.
60. Wang Z, Leng Y, Tsai LK, Leeds P, Chuang DM: Valproic acid attenuates
blood–brain barrier disruption in a rat model of transient focal cerebral
ischemia: the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow
Metab 2011, 31:52–57.
doi:10.1186/1742-2094-10-80
Cite this article as: Li et al.: Disruption of the blood–brain barrier after
generalized tonic-clonic seizures correlates with cerebrospinal fluid
MMP-9 levels. Journal of Neuroinflammation 2013 10:80.
Li et al. Journal of Neuroinflammation 2013, 10:80 Page 9 of 9
http://www.jneuroinflammation.com/content/10/1/80
